Overview

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

Status:
Terminated
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The investigators' hypothesis is that pretreating patients with COPD with inhaled treprostinil prior to pulmonary rehabilitation sessions will result in improved exercise tolerance during sessions. This in turn will lead to an increased response to pulmonary rehabilitation, resulting in improved exercise tolerance and quality of life.
Phase:
Phase 2
Details
Lead Sponsor:
Inova Health Care Services
Treatments:
Treprostinil